Preclinical testing of drug-induced proarrhythmia: value of transgenic models.
Cardiovasc Hematol Agents Med Chem
; 5(4): 289-94, 2007 Oct.
Article
en En
| MEDLINE
| ID: mdl-17979691
Drug-induced proarrhythmia is a serious medical problem that causes relevant morbidity and mortality. It is also a relevant problem for the development of novel pharmacological compounds. Therefore, there is a need for sensitive, specific and high-throughput preclinical tests to detect a risk for drug-induced proarrhythmia early in the development of new drugs. The review focuses on the potential role of transgenic models with altered repolarisation but without overt structural heart disease for drug-induced proarrhythmia screening. Today, selected murine models with alterations in K+, Na+ channels and ankyrin are available. In the future, transgenic rabbit and Zebra fish models may also be used.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Arritmias Cardíacas
/
Potenciales de Acción
/
Antiarrítmicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Cardiovasc Hematol Agents Med Chem
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
/
FARMACOLOGIA
/
HEMATOLOGIA
/
QUIMICA
/
QUIMICA CLINICA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Alemania
Pais de publicación:
Países Bajos